Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - azacitidine -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mega lifesciences sdn. bhd. - azacitidine -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - azacitidine -

Israel - englanti - Ministry of Health

bristol, myers squibb (israel) limited, israel - azacitidine - film coated tablets - azacitidine 200 mg - azacitidine - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy

Israel - englanti - Ministry of Health

bristol, myers squibb (israel) limited, israel - azacitidine - film coated tablets - azacitidine 300 mg - azacitidine - onureg is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following intensive induction chemotherapy and are not able to complete intensive curative therapy

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine ans is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine lws is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine sxp is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),,? chronic myelomonocytic leukaemia [cmmol (10-29 percent marrow blasts without myeloproliferative disorder)],,? acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine epsl is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine eugia is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.